Preview

Современная ревматология

Расширенный поиск

Эффективность и переносимость эторикоксиба у больныхактивным анкилозирующим спондилитом: обзор литературы

https://doi.org/10.14412/1996-7012-2010-644

Полный текст:

Об авторе

А. Г. Бочкова



Литература

1. <div><p>Braun J., Pham T., Sieper J. et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;62:817-24.</p><p>Appel H., Kuhne M., Spiekermann S. et al. Immunohistologic Analysis of Zygapophyseal Joints in Patients With Ankylosing Spondylitis. Arthr Rheum 2006 Sep 54(9);2845-51.</p><p>Boersma J.W. Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazon. Scand J Rheumatol 1976;5:60-4.</p><p>Wanders A., Van der Heijde D., Landewe R. et al. Nonsteroidal anti- inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis. Arthr Rheum 2005;52:1756-65.</p><p>Zhang X., Schwarz E.M., Young D.A. et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Ivest 2002;109:1405-15.</p><p>Rudwaleit M., Niewerth M., Listing J. et al. Disease activity over one year in early ankylosing spondylitis in a prospective observational cohort (GESPIC) (abstract). Ann Rheum Dis 2005;64(Suppl.III):65.</p><p>Van der Heijde D., Baraf H.S.B., Ramos-Remus C. et al. Evalution of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthr Rheum 2005;52:1205-15.</p><p>Song I.H., Poddubny D.A., Rudwaleit M. et al. Benefits and Risks of Ankylosing Spondylitis Treatment with Nonsteroidal Antiinflammatory Drugs. Arthr Rheum 2008;58:929-38.</p><p>Laine L., Curtis S.Р., Cryer B. et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised controlled trial. Lancet 2007;369:465-73.</p><p>Gabriel S.E., Jaakkimainen I., Bombardier C. Risk for serious gastrointestitinal complications relatd to use of nonsteroidal anti-inflammatory drugs: a meta-analisis. Ann Intern Med 1991;115:787-96.</p><p>Dougados M., Simon P., Braun J. et al. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis 2010 Sep 9 [Epub ahead of print].</p><p>Zhang X., Schwarz E.M., Young D.A. et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Ivest 2002;109:1405-15.</p><p>Van der Heijde D., Baraf H.S.B., Ramos-Remus C. et al. Evalution of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthr Rheum 2005;52:1205-15.</p><p>Gabriel S.E., Jaakkimainen I., Bombardier C. Risk for serious gastrointestitinal complications relatd to use of nonsteroidal anti-inflammatory drugs: a meta-analisis. Ann Intern Med 1991;115:787-96.</p><p>Miedany E.I., Youssef S., Ahmed I. et al. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel disease. Inflamm Bowel dis 2004;10:751-7.</p><p>Rudwaleit M., Niewerth M., Listing J. et al. Disease activity over one year in early ankylosing spondylitis in a prospective observational cohort (GESPIC) (abstract). Ann Rheum Dis 2005;64(Suppl.III):65.</p><p>Sieper J., Klopsch T., Richter M. et al. Comparison of 2 different dosages of celecoxib with diclofenac for the treatment of active AS: results of a 12-week randomized double-blind controlled study. Ann Rheum Dis 2008 Mar;67(3):323-9.</p><p>Jarrett S.J., Sivera F., Cawkwell L.S. et al. MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib. Ann Rheum Dis 2009 Sep;68(9):1466-9.</p><p>Croom K.F., Siddiqui M.A. Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis. Drugs 2009 Jul 30;69(11):1513-32.</p><p>Jansen J.P., Gaugris S., Choy E.H. et al. Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis. Pharmacoeconomics 2010 Apr 1;28(4):323-44.</p><p>Cannon C.P., Curtis S.P., FitzGerald G.A. et al. Cardiovascular outcomes with etoricoxib nd diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Longterm (MEDAL) programme: a randomized comparison. Lancet 2006;368:1771-81.</p><p>Moore R.A., Derry S., McQuay H.J. Discontinuation rates in clinical trials in musculoskeletal pain: meta-analis from etorycoxib clinical trial reports. Arthr Res Ther 2008;10(3):R53.</p></div><br />


Для цитирования:


Бочкова А.Г. Эффективность и переносимость эторикоксиба у больныхактивным анкилозирующим спондилитом: обзор литературы. Современная ревматология. 2010;4(4):89-92. https://doi.org/10.14412/1996-7012-2010-644

For citation:


Bochkova A.G. Effektivnost' i perenosimost' etorikoksiba u bol'nykhaktivnym ankiloziruyushchim spondilitom: obzor literatury. Modern Rheumatology Journal. 2010;4(4):89-92. (In Russ.) https://doi.org/10.14412/1996-7012-2010-644

Просмотров: 857


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)